Literature DB >> 17624247

N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection.

A Garozzo1, G Tempera, D Ungheri, R Timpanaro, A Castro.   

Abstract

Many studies have shown that oxidative stress is important in the pathogenesis of pulmonary damage during influenza virus infections. Antioxidant molecules are therefore potentially useful against viral infection. Our previous studies show that N-acetylcysteine (NAC) has a protective effect in a model of lethal influenza infection in mice. NAC administration significantly decreased the mortality in infected mice. Further studies have demonstrated that NAC enhanced survival in combination with the antiviral agent ribavirin. In the present study, we report the effect of combined treatment with NAC and Oseltamivir, clinically used in the treatment and prevention of influenza virus infection, in a murine model of lethal influenza infection. NAC was given as a single daily dose of 1000 mg/kg starting from 4 h before infection and until day 4 after infection; Oseltamivir was given twice daily at dose of 1 mg/kg/die for 5 days, starting from 4 h before infection. End-point evaluation was 21-days survival. NAC alone was slightly effective (20%), since a suboptimal treatment was used. Survival increased to 60% with Oseltamivir and to 100% with Oseltamivir and NAC used in combination. Since NAC alone does not show any antiviral action, the present findings suggest that antioxidant therapy increase survival by an improvement in host defense mechanisms, and/or by a direct antioxidant effect against oxidative stress associated with viral infection. Our studies demonstrate the effectiveness of combining agents acting through different mechanisms, such as antiviral drugs oseltamivir and the antioxidant NAC, indicating a possible advantage of combining the two treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624247     DOI: 10.1177/039463200702000215

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  29 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

Review 2.  Inflammatory and oxidative stress in rotavirus infection.

Authors:  Carlos A Guerrero; Orlando Acosta
Journal:  World J Virol       Date:  2016-05-12

3.  Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Authors:  Neal Van Hoeven; Jessica A Belser; Kristy J Szretter; Hui Zeng; Peter Staeheli; David E Swayne; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

4.  The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.

Authors:  Lindsay Hill-Batorski; Peter Halfmann; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

5.  Role of glutathione in immunity and inflammation in the lung.

Authors:  Pietro Ghezzi
Journal:  Int J Gen Med       Date:  2011-01-25

6.  Combination chemotherapy for influenza.

Authors:  Elena A Govorkova; Robert G Webster
Journal:  Viruses       Date:  2010-07-27       Impact factor: 5.818

7.  N-acetylcysteine lacks universal inhibitory activity against influenza A viruses.

Authors:  Mutien-Marie O Garigliany; Daniel J Desmecht
Journal:  J Negat Results Biomed       Date:  2011-05-09

Review 8.  Intracellular redox state as target for anti-influenza therapy: are antioxidants always effective?

Authors:  Rossella Sgarbanti; Donatella Amatore; Ignacio Celestino; Maria Elena Marcocci; Alessandra Fraternale; Maria Rosa Ciriolo; Mauro Magnani; Raffaele Saladino; Enrico Garaci; Anna Teresa Palamara; Lucia Nencioni
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

9.  Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors.

Authors:  Carlos Arturo Guerrero; Victor Rodriguez Paula Pardo; Orlando Acosta Rafael Guerrero
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

Review 10.  How to approach and treat viral infections in ICU patients.

Authors:  Theodoros Kelesidis; Ioannis Mastoris; Aliki Metsini; Sotirios Tsiodras
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.